| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $0 | 0 | 0 |
Sells | $241,951 | 23 | 100 |
| Smalling Ralph | Head of Regulatory | 0 | $0 | 8 | $11,545 | $-11,545 |
| Cappello Joseph | Chief Technical Officer | 0 | $0 | 4 | $18,353 | $-18,353 |
| Yu Yong | SVP, Clinical Development | 0 | $0 | 4 | $20,023 | $-20,023 |
| Zindrick Thomas | President and CEO | 0 | $0 | 4 | $83,264 | $-83,264 |
| Thomas John | director | 0 | $0 | 3 | $108,766 | $-108,766 |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Over the last 12 months, insiders at Genelux Corporation have bought $0 and sold $241,951 worth of Genelux Corporation stock.
On average, over the past 5 years, insiders at Genelux Corporation have bought $536,625 and sold $5.52M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $10,000 was made by Yu Yong (VP, Clinical Trial Operations) on 2024‑05‑29.
| 2026-06-03 | Sale | Smalling Ralph | Head of Regulatory | 192 0.0005% | $2.93 | $563 | +4.14% | |
| 2026-06-01 | Sale | Thomas John | director | 10,000 0.0267% | $2.98 | $29,801 | -0.17% | |
| 2026-05-11 | Sale | Zindrick Thomas | President and CEO | 2,798 0.0075% | $2.94 | $8,226 | +2.67% | |
| 2026-05-11 | Sale | Cappello Joseph | Chief Technical Officer | 605 0.0016% | $2.97 | $1,799 | +2.67% | |
| 2026-05-11 | Sale | Yu Yong | Chief Scientific Officer | 605 0.0016% | $2.97 | $1,798 | +2.67% | |
| 2026-05-11 | Sale | Smalling Ralph | Head of Regulatory | 270 0.0007% | $2.98 | $804 | +2.67% | |
| 2026-03-25 | Sale | Smalling Ralph | Head of Regulatory | 240 0.0006% | $2.51 | $602 | +4.91% | |
| 2026-03-24 | Sale | Zindrick Thomas | President and CEO | 3,582 0.0095% | $2.42 | $8,668 | +14.46% | |
| 2026-03-24 | Sale | Cappello Joseph | Chief Technical Officer | 906 0.0024% | $2.42 | $2,193 | +14.46% | |
| 2026-03-24 | Sale | Yu Yong | SVP, Clinical Development | 906 0.0024% | $2.42 | $2,193 | +14.46% | |
| 2026-03-24 | Sale | Smalling Ralph | Head of Regulatory | 345 0.0009% | $2.42 | $835 | +14.46% | |
| 2026-03-02 | Sale | Thomas John | director | 10,000 0.0258% | $2.90 | $28,957 | -7.88% | |
| 2025-12-05 | Sale | Smalling Ralph | Head of Regulatory | 165 0.0004% | $4.69 | $774 | -40.41% | |
| 2025-12-01 | Sale | Thomas John | director | 10,000 0.0268% | $5.00 | $50,008 | -43.37% | |
| 2025-11-17 | Sale | Zindrick Thomas | President and CEO | 4,509 0.0121% | $5.37 | $24,211 | -46.67% | |
| 2025-11-17 | Sale | Cappello Joseph | Chief Technical Officer | 973 0.0026% | $5.37 | $5,224 | -46.67% | |
| 2025-11-17 | Sale | Yu Yong | SVP, Clinical Development | 973 0.0026% | $5.37 | $5,224 | -46.67% | |
| 2025-11-17 | Sale | Smalling Ralph | Head of Regulatory | 343 0.0009% | $5.37 | $1,842 | -46.67% | |
| 2025-09-03 | Sale | Smalling Ralph | Head of Regulatory | 580 0.0016% | $3.36 | $1,948 | -9.29% | |
| 2025-08-21 | Sale | Zindrick Thomas | President and CEO | 12,673 0.0324% | $3.33 | $42,159 | -11.48% |
| Zindrick Thomas | President and CEO | 532051 1.4144% | $1.56M | 1 | 7 | <0.0001% |
| Thomas John | director | 472784 1.2568% | $1.39M | 1 | 7 | <0.0001% |
| Cappello Joseph | Chief Technical Officer | 154549 0.4108% | $452,828.57 | 0 | 7 | |
| Yu Yong | Chief Scientific Officer | 149706 0.398% | $438,638.58 | 1 | 19 | <0.0001% |
| Smalling Ralph | Head of Regulatory | 67611 0.1797% | $198,100.23 | 1 | 11 | <0.0001% |
| Szalay Aladar | 10 percent owner | 599821 1.5946% | $1.76M | 0 | 42 | |
| Ryder Sean | General Counsel | 47621 0.1266% | $139,529.53 | 1 | 4 | <0.0001% |
| Tyree James L | director | 45791 0.1217% | $134,167.63 | 1 | 3 | <0.0001% |
| Zak Lourie S. | Chief Financial Officer | 40802 0.1085% | $119,549.86 | 1 | 1 | <0.0001% |
| Jewett Caroline | Head of Quality | 16174 0.043% | $47,389.82 | 0 | 2 | |
| Smither John W | director | 13170 0.035% | $38,588.10 | 1 | 1 | <0.0001% |
| Mirabelli Mary | director | 12460 0.0331% | $36,507.80 | 1 | 0 | <0.0001% |
| Samuelson Doug | Chief Financial Officer | 2303 0.0061% | $6,747.79 | 0 | 1 | |
| Zhang Qian | Associate VP, Research | 200 0.0005% | $586.00 | 1 | 0 | +278.21% |
$9,405,928 | 107 | 12.61% | $94.77M | |
$84,898,333 | 58 | 18.32% | $98.32M | |
$66,137,559 | 49 | 6.29% | $140.65M | |
$18,994,888 | 46 | 88.59% | $102.55M | |
$140,595,157 | 34 | 17.93% | $134.5M | |
$38,601,028 | 29 | 1.18% | $104.68M | |
$161,692,548 | 20 | 18.00% | $121.3M | |
$178,593,887 | 15 | -14.86% | $112.88M | |
$11,267,080 | 15 | -22.36% | $94.92M | |
$17,741,707 | 13 | 30.23% | $112.77M | |
$515,321 | 12 | -2.55% | $126.02M | |
Genelux Corporation (GNLX) | $1,073,250 | 10 | 19.46% | $110.22M |
$9,999,920 | 10 | -40.03% | $106.7M | |
$13,919,584 | 9 | -30.43% | $105.64M | |
$43,387,736 | 8 | 80.63% | $97.53M | |
$99,355,998 | 7 | -65.74% | $130.23M | |
$68,692,148 | 6 | -39.10% | $98.42M | |
$2,857,000 | 2 | -5.23% | $131.01M | |
$12,750 | 2 | -39.73% | $147.95M |
| Increased Positions | 40 | +71.43% | 2M | +23.36% |
| Decreased Positions | 16 | -28.57% | 150,183 | -2.01% |
| New Positions | 20 | New | 813,634 | New |
| Sold Out Positions | 4 | Sold Out | 56,948 | Sold Out |
| Total Postitions | 80 | +42.86% | 9M | +21.35% |
| Woodward Diversified Capital, Llc | $8,391.00 | 4.85% | 1.84M | +65,813 | +3.7% | 2025-09-30 |
| Vanguard Group Inc | $6,458.00 | 3.74% | 1.42M | -34,465 | -2.37% | 2025-09-30 |
| Bleichroeder Lp | $3,249.00 | 1.88% | 714,000 | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $1,728.00 | 1% | 379,888 | +54,905 | +16.89% | 2025-09-30 |
| Geode Capital Management, Llc | $1,610.00 | 0.93% | 353,840 | +35,015 | +10.98% | 2025-09-30 |
| Bank Of America Corp /De/ | $1,472.00 | 0.85% | 323,494 | -85,198 | -20.85% | 2025-09-30 |
| Flputnam Investment Management Co | $1,366.00 | 0.79% | 300,290 | +263,131 | +708.12% | 2025-09-30 |
| Alyeska Investment Group, L.P. | $1,297.00 | 0.75% | 285,000 | 0 | 0% | 2025-09-30 |
| Global Retirement Partners, Llc | $1,040.00 | 0.6% | 228,676 | 0 | 0% | 2025-09-30 |
| Provident Wealth Management, Llc | $708.00 | 0.41% | 155,670 | -3,197 | -2.01% | 2025-09-30 |